ArticleFrontiers in oncology2026
The effect of adjuvant imatinib treatment for patients with high-risk gastrointestinal stromal tumor.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Imatinib mesylate (IM) has changed the management of gastrointestinal stromal tumors (GISTs), especially for adjuvant therapy after radical resection. However, the optimal duration of the adjuvant therapy remains controversial. Therefore, this study evaluated the effect of adjuvant IM duration and plasma drug concentrations on survival outcomes of patients at high risk with GISTs. Methods: We retrospectively analyzed patients diagnosed with high-risk GIST who underwent radical surgery at the First Affiliated Hospital of Chongqing Medical University between January 2008 and December 2021. Survival outcomes were compared according to adjuvant IM duration (≤3 years vs. >3 years). Plasma trough concentrations (Cmin) of IM were measured in a subset of patients and analyzed in relation to prognosis. Results: This study included 75 patients (42 males and 33 females), with a median age of 53 (24-79) years. Tumors were most commonly located in the small intestine (44 patients, 58.7%) and stomach (23 patients, 30.7%). Kaplan-Meier curve analysis showed that the 5-year relapse-free survival (RFS) rates were 84% and 74% in the groups with treatment duration >3 years and ≤3 years, respectively (P < 0.05), whereas no significant difference in 5-year overall survival (OS) was observed between the two groups (P > 0.05). In the multivariate analysis, treatment duration was not significantly associated with survival benefit (HR = 0.53, 95% CI 0.15-1.83, P = 0.313). Conclusion: Based on this retrospective study, adjuvant IM for more than 3 years did not independently improve prognosis in patients with high-risk GIST following radical resection. Moreover, the clinical significance of IM Cmin remains unclear. Therefore, extending adjuvant therapy beyond 3 years is not routinely recommended at present. These findings require further validation through prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.